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Abstract
Metabolic syndrome plays a vital role in present-day primary care. The ICD-10 diagnostic
coding for this set of symptoms more comprehensively identifies patients with increased risk of
cardiovascular events and comorbidities. Metabolic syndrome affects one-third of adults in the
US and is defined as the presence of three of the following characteristics: abdominal obesity,
hypertension, elevated triglycerides, low high-density lipoprotein, and elevated fasting plasma
glucose. Proper screening for metabolic syndrome can identify complex patients before
conditions like hypertension or type II diabetes develop. Management of metabolic syndrome
emphasizes prevention and prioritizes lifestyle modifications as first-line treatment. Despite
strong evidence supporting the use of metabolic syndrome as a key diagnostic code, it is not
being routinely identified and documented in primary care. Moreover, without proper screening,
identification, and coding for metabolic syndrome in primary care, management and lifestyle
modifications may not be initiated in a timely way or at all. This shows evidence of the large gap
between what we know about metabolic syndrome and how to identify it and what is actually
happening in primary care. Purpose: To address this gap, a DNP project was implemented at
two primary care sites. Its purpose was to increase primary care provider knowledge,
identification, and ICD-10 coding of metabolic syndrome, leading to better office visit follow-up
and enhanced patient outcomes. Toolkit: A toolkit was developed based on the 2009 American
College of Preventive Medicine Metabolic Syndrome Time Tool and accompanying verbal
presentation with a PowerPoint. The intervention was provided live at two primary care sites to
healthcare staff, including providers (NP, PA, MD) and nurses (RN, LPN). Outcomes: Valuable
data were obtained regarding enhancement of provider knowledge and perceptions of metabolic
syndrome, as well as their engagement with and use of the toolkit. Conclusion: Use of metabolic
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syndrome as a key ICD code is supported by strong evidence, primary care providers are
amenable to its use, yet remain slow to adapt it into their medical records systems. Further
investigation in this area is needed.
Keywords: metabolic syndrome, abdominal obesity, American College of Preventive Medicine,
atherosclerotic disease, elevated fasting plasma glucose level, elevated triglycerides, exercise,
hypertension, lifestyle management, low HDL, type II diabetes, Metabolic Syndrome Time Tool,
primary care, toolkit

3

IDENTIFYING PATIENTS WITH METABOLIC SYNDROME

4

Background and Evidence of Problem
This paper chronicles a Doctor of Nursing Practice (DNP) Project regarding metabolic
syndrome identification in the primary care setting. Over time investigative work toward
defining metabolic syndrome has been driven by healthcare providers trying to understand the
effect and impact of a cluster of frequently occurring coexistent physical characteristics on
patients’ increased risks for cardiovascular disease and diabetes (Meisinger, Koletzko, &
Heinrich, 2006; Sarafidis & Nilsson, 2006). Metabolic syndrome is a serious health problem and
primary care providers should include metabolic syndrome in primary care.
Almost a century ago, scientists began to describe the common coexistence of various
components of metabolic syndrome. In 1923, Eskil Kylin described the clustering of
hypertension, hyperglycemia, and gout. In 1947, French physician Dr. Jean Vague reported that
upper body obesity is often associated with certain metabolic abnormalities. In 1975, Hermann
Haller introduced the term metabolic syndrome (Haller & Hanefeld, 1975). Modern recognition
of metabolic syndrome began in the 1980s with Dr. Gerald Reaven and continued into the 1990s
as large organization such as the World Health Organization became involved (Alberti &
Zimmet, 1998; Reaven 1988; 2005). Subsequently, in 2001, the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) developed the current
definition of metabolic syndrome.
Over the past two decades, many organizations have developed definitions and guidelines
to manage metabolic syndrome, including the American College of Cardiology, American Heart
Association (AHA) and National Heart Lung Blood Institute (NHLBI), American Diabetes
Association (ADA), and International Diabetes Federation (IDF). At present, there are two most
widely accepted definitions from the AHA/NHLBI ATP III Update and the IDF. However, there
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have not been new updates to existing guidelines since 2005 – 2009, depending on the
organization.
Metabolic syndrome is an aggregate of physical characteristics and risk factors that
greatly affect health and quality of life yet can be preventable. Metabolic syndrome encapsulates
many comorbidities and complications, related to the individual characteristics and diseases
making up the syndrome. The five characteristics of metabolic syndrome include abdominal
obesity, hypertension, elevated triglycerides, reduced HDL cholesterol, and elevated fasting
plasma glucose level (Ervin, 2009; Grundy et al., 2005; IDF, 2006; Mallory, Angosta, & Kawi,
2014; National Health Institute (NIH), 2004).
One third of adults in the US and one quarter of adults in the world have metabolic
syndrome (IDF, 2006; Mozumdar & Liguori, 2011). The risk of metabolic syndrome increases
most significantly with obesity, which is apparent when comparing the prevalence of metabolic
syndrome to a rise in obesity rates (AHA, 2014; Ervin, 2009). In fact, the increase in obesity rate
is occurring despite mounting awareness of the condition and efforts to prevent or treat those at
risk or affected by the syndrome. Additionally, abdominal obesity has been shown to have more
complications than lower body fat because of the proximity of fat cells to the liver, which plays
important roles in metabolism (Ferranti & Mozaffarian, 2008) .
There are many comorbidities and complications associated with metabolic syndrome.
These can be identified looking at metabolic syndrome as a whole, as well as the known
outcomes of the individual characteristics. These characteristics, diseases, comorbidities, and
complications create a complex, interconnected web of body systems problems. For example,
elevated fasting plasma glucose is one characteristic of metabolic syndrome and if it progresses
to diabetes, comorbidities and complications may include heart disease, stroke, kidney failure,
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blindness, neuropathy, and digit or limb amputation (Caro, Ward, & O’Brien, 2002; Centers for
Disease Control and Prevention [CDC], 2014). Furthermore, abdominal obesity is a risk factor
for cardiovascular disease and hyperlipidemia is a risk factor for heart attack, stroke, heart
disease, coronary artery disease, and peripheral vascular disease (Fiegal, Kit, Orpana, &
Graubard, 2013; National Cholesterol Education Program [NCEP], 2002). Hypertension
complications include heart failure, left ventricular hypertrophy, ischemic stroke, intracerebral
hemorrhage, heart disease, myocardial infarction, chronic kidney disease, and end-stage renal
disease (Egan, Zhao, & Axon, 2010). Low HDL is a biomarker inversely related with
cardiovascular disease and coronary heart disease (Mackey et al., 2012). As a result, any
complications, combined or individual, can have detrimental effects on patient’s well-being.
Due to the aforementioned characteristics of metabolic syndrome such as hypertension,
obesity, and diabetes, metabolic syndrome has significant societal and financial implications.
According to the CDC (2014), the estimated annual medical cost of the total direct and indirect
costs of diabetes during 2012 was $254 billion. The annual medical cost of obesity is estimated
at $147 billion. In 2011, total cost associated with hypertension was $46 billion (CDC, 2013).
These staggering annual medical costs will continue to increase with the increased prevalence of
metabolic syndrome.
Age, race, and weight are the most influential factors for developing metabolic syndrome
(IDF, 2006; Park et al., 2013). Those at highest risk include individuals that are obese, MexicanAmerican, or women. Other risk factors include postmenopausal status, smoking, low household
income, high carbohydrate diet, and physical inactivity. All of these risk factors can be managed
in primary care. Many patients are identified with individual characteristics of metabolic
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syndrome such as obesity or hypertension but often times, metabolic syndrome is not identified
as a primary diagnosis, which may result in inadequate treatment interventions (ACPM, 2009).
Successful diagnosis of metabolic syndrome can lead to better treatment and improved quality of
life, therefore limiting complications and decreasing or eliminating preventable healthcare costs
(AHA, 2014).
Problem Statement
Risk of metabolic syndrome among adults is increasing, both locally and globally, and it
affects an estimated one third of adults in the US. An extensive review of the literature revealed
that although the prevalence of metabolic syndrome is high when a population is screened, those
percentages were based on individual studies’ or organizations’ assessment of a population, not
the presence of a metabolic syndrome diagnosis coded by a primary care provider (ACPM,
2009). This led the DNP student to understand that metabolic syndrome identification and
documentation are not widely used in primary care. It was speculated that metabolic syndrome is
being under-coded and thus under-recognized. Adequately identifying patients with metabolic
syndrome is the first step to clinically addressing this complex problem.
Review of the Literature
The focus of this review of literature was on the metabolic syndrome definition,
management, and use of International Classification of Diseases (ICD) coding. An extensive
review, including the journal Metabolic Syndrome and Related Disorders (2015), revealed
hundreds of articles identifying research related to the pathophysiology and extensive effects of
metabolic syndrome. This search yielded over 15,000 articles and guidelines. Inclusion criteria
consisted of peer reviewed, full-text articles published in the English language within the past ten
years, concerning adults greater than eighteen years old. Based on title and abstract, the results
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were further narrowed down to forty-five. After further review of each text, thirteen articles
published from 2002 – 2014 were retained.
There are numerous practice guidelines related to the management of metabolic
syndrome, however many of these guidelines are dated based on preferred standards for evidence
based research. Additionally, based on the review of the literature, it was noted that there is a
significant amount of information known about metabolic syndrome but not effective application
of metabolic syndrome as a diagnostic code in primary care; as demonstrated by the fact that
providers are not routinely identifying or documenting metabolic syndrome. Moreover, the
search did not yield even one reviewed article where the authors utilized existing data on patients
with metabolic syndrome in a primary care practice. Hence, the review of the literature
demonstrated a gap in the diagnosis and identification of metabolic syndrome.
There were two highlights from this review of literature, including the American Heart
Association/National Heart, Lung, and Blood Institute Scientific Statement from 2005 that used
the Adult Treatment Panel III’s 2002 metabolic syndrome definition. This guideline is favored
because of the ease of use in the primary care setting and focus on lifestyle management. The
second highlight was the American College of Preventive Medicine’s (ACPM) Metabolic
Syndrome Time Tool. This is an important guide in the diagnosis and treatment of metabolic
syndrome, as it was identified in the literature review as the most thorough and evidence based
resource for this DNP Project.
The most current guidelines and recommendations come from the 2005 AHA/NHLBI
Diagnosis and Management of the Metabolic Syndrome (Grundy et al., 2005) and the 2006
International Diabetes Foundation Consensus Worldwide Definition of the Metabolic Syndrome.
The AHA/NHLBI Management of the Metabolic Syndrome is an update of the 2002 Adult
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Treatment Panel III (ATP III) Guidelines from the National Cholesterol Education Program
(NCEP, 2002). The updated 2005 ATP III criteria were used in the presentation and toolkit due
to their vast acceptance, ease of application and use in the clinic setting. In 2009, the Metabolic
Syndrome Time Tool was released based on the ATP III and a synthesis of the most up-to-date
information at the time.
The Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at
Metabolic Risk, an Endocrine Society Clinical Practice Guidelines also provides guidelines for
managing metabolic risk (Rosenzweig et al., 2008). This guideline provides similar information
to the IDF (2006), ATP III (2002), and AHA/NHLBI (2005) release. Guidelines that further
influenced the Metabolic Syndrome Time Tool (American College of Preventive Medicine
[ACPM], 2009) include the Physical Activity Guideline from the American College of Sports
Medicine and the AHA, Treatment of Metabolic Syndrome from the Finnish Medical Society,
and Screening for Metabolic Syndrome in Adults–University of Texas at Austin, Family Nurse
Practitioner Program, and Diet Guideline from the U.S. Preventive Services Task Force.
There is little controversy or discourse in suggestions for the management of metabolic
syndrome between the guidelines. All guidelines recommend early diagnosis, regular screening,
and lifestyle therapy as the primary intervention. The most effective setting for early diagnosis,
regular screening, and lifestyle therapy is the primary care setting. There is a consensus among
the most prominent organizations and the most notable researchers in the field, who
acknowledge physical activity to be superior (Alberti et al., 2009; ACPM, 2009; American
College of Sports Medicine [ACSM], 2006; Brewer, 2003; CDC, 2013; Eckel, Grundy, &
Zimmet, 2005; IDF, 2006; Mottillo et al., 2010).
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The AHA/NHLBI (Grundy et al., 2005) maintained the ATP III 2002 criteria for
metabolic syndrome due to the simplicity of use in a clinical setting and the advantage of
avoiding emphasis of one characteristic. The Endocrine Society (Rosenzweig et al., 2008)
recommended using the AHA/NHLBI definition, also based on simplicity and convenience in
the outpatient primary care setting. The ATP III and AHA/NHLBI defined metabolic syndrome
by the presence of (or treatment of) three or more of the following: abdominal obesity (waist
circumference ≥ 35” in females, 40” in males), hypertension (≥ 130/85 or receiving
antihypertensive therapy), elevated triglycerides (≥ 150 mg/dl or receiving anti-lipid therapy),
reduced HDL (< 50 mg/dl in females, < 40 mg/dl in males), and an elevated fasting plasma
glucose level (≥ 100 mg/dl; NCEP, 2002).
The International Diabetes Foundation (IDF) (2006) guideline, like the AHA/NHLBI
(2005) and Endocrine Society (2008), was based on the 2002 ATP III. The IDF (2006) definition
differs in the inclusion of ethnicity-based waist circumference guidelines. These ethnicity-based
waist circumference guidelines identify seven different national or ethnic groups. Europoid
males are identified with abdominal obesity if waist circumference is > 94 cm, Europoid females
> 80 cm. South Asian males are identified with abdominal obesity if waist circumference is > 90
cm, South Asian females > 80 cm. Chinese and Japanese males and females are recommended to
follow the South Asian recommendations. Sub-Saharan Africans and Eastern Mediterranean and
Middle East populations are recommended to use Europoid recommendations. These
recommendations may change in the future, as more specific data are available.
The Endocrine Society’s clinical guidelines further elaborated on managing metabolic
risks associated with this syndrome (Rosenzweig et al., 2008). The Endocrine Society (2008)
recommends screening for the main components of metabolic syndrome at regular intervals (at
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least every 3 years) in individuals who have one or more risk factors but do not meet the
established definitions of the syndrome. Waist circumference should be measured as a routine
part of the clinical examination but does not replace measurement of weight or BMI. Individuals
previously diagnosed with prediabetes should be screened for type II diabetes at 1–2-year
intervals. Patients with metabolic syndrome should have 10-year risk assessment for coronary
heart disease or cardiovascular disease done using the Framingham, Prospective Cardiovascular
Munster scoring, or European SCORE algorithm.
The most notable differences between the IDF (2006) and prior guidelines focus on
weight management and weight loss goals during the first year of intervention. The IDF
recommends five to ten percent body weight reduction whereas earlier AHA/NHLBI and ATP
III guidelines recommended seven to ten percent reduction. This difference toward a more “userfriendly” weight loss goal reflects the evidence that even a small amount of weight loss has
clinical benefit. The Endocrine Society (Rosenzweig et al., 2008) panel concurs with the IDF
(2006). They further suggest that weight loss, even in small increments, should continue beyond
the first year until a determined weight loss goal is achieved. However, patients should
understand that any amount of weight loss has benefit.
Once diagnosed, patients with metabolic syndrome need to be managed steadfastly to
reduce the risk of cardiovascular disease and type II diabetes (AHA/NHLBI, 2005; IDF, 2006).
Lifestyle changes are first-line therapy and the focus of primary intervention. These changes
should be led by an activity and dietary plan. Activity can lead to weight loss, and weight loss
can lead to lean gain. Patients’ activity goals and weight loss goals will need to be adjusted over
time and should be rechecked repeatedly. Secondary intervention, including drug therapy should
be instituted when lifestyle modification is not sufficient to reach predefined goals and
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individuals are at high risk for cardiovascular disease. Diet recommendations include reduced
intake of saturated fat, transfat, and cholesterol. Patients should participate in moderate-intensity
physical activity for at least 150 minutes a week, with 30 minutes of continuous or intermittent
physical activity per day at least 5 days a week. A combination of aerobic and anaerobic exercise
is most effective (Grundy et al., 2005). All of these recommendations are part of proper
treatment, which can only be accomplished if adequate diagnosis is done.
The Metabolic Syndrome Time Tool (ACPM, 2009) is a comprehensive guide for
providers regarding metabolic syndrome, based on the ATP III definition. It
provides rationales and information regarding the diagnosis, controversy, importance in clinical
practice, lifestyle management, challenges in primary care, guide to the office visit,
pharmacotherapy, and follow-up plan. The American College of Preventive Medicine also offers
a Metabolic Syndrome Clinical Reference Page and A Guide For Patients to accompany the
Time Tool. The Time Tool (ACPM, 2009) emphasizes what the purpose of identifying metabolic
syndrome is and why treating it is important. The authors emphasize that metabolic syndrome is
a syndrome, not a global risk predictor. Having metabolic syndrome doubles the risk for
cardiovascular disease, which is five times the risk for type II diabetes alone. Metabolic
syndrome identifies those at risk for health problems, especially cardiovascular disease and type
II diabetes. It adds to cardiovascular disease risk beyond LDL cholesterol, emphasizes the
detrimental effects of central fat accumulation, allows for quantification of lifestyle risk, and
alerts that lifestyle modifications are needed immediately. Metabolic syndrome is vital in
primary practice.
Challenges for primary care for providers are to recognize metabolic syndrome, code for
it, evaluate associated risk conditions, develop a medical plan, educate patients on why
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recognition it is important, discuss needed lifestyle modifications and plan for achieving them.
There is great need for an efficient approach to address all of this.
The most logical critique of metabolic syndrome in primary care is that treatment of the
syndrome is not different from treatment for each of its components (Kahn et al., 2005).
However, after a thorough investigation of this syndrome, this DNP student has found that
acknowledgement of metabolic syndrome as a comprehensive diagnosis is consistent with
treating the patient as a whole person and in addressing the ‘big picture’, mirroring healthcare via
the nursing model. A focus on primary care and prevention at primary, secondary, and tertiary
levels is congruent with the current US healthcare initiatives of Healthy People 2020 (USDHHS,
2014) and the Affordable Care Act. Also, if coded properly for metabolic syndrome, follow-up
visits qualify for a more comprehensive visit, over more time, to assess and counsel.
The Cardiometabolic Think Tank is a committee comprised of metabolic syndrome
experts working to define new patient care models (Sperling et al., 2015). Consensus agreement
of the think tank panel confirmed the definition of metabolic syndrome as a “complex
pathophysiological state comprised of a cluster of clinically measured and typically unmeasured
risk factors, is progressive in its course, and is associated with serious and extensive comorbidity
but tends to be clinically under-recognized” (p. 3). The Think Tank panel reported that metabolic
syndrome must be accurately identified as a diagnosis, and that ideally, those at risk for
metabolic syndrome will be identified before the syndrome even develops. It is anticipated that
since the 2015 Think Tank report was published, new guidelines for identification, diagnosis and
managing of metabolic syndrome will be forthcoming. Until then, the AHA/NHLBI Guideline
and the ACPM Time Tool, although older sources, are still the most current, widely accepted,
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and best options available for comprehensive evidence based recommendations for screening,
identification, coding, and management of metabolic syndrome in the primary care setting.
Theoretical Framework
This project was guided by Program Theory (2005) and Lewin’s Theory of Change
(1947). The Program Theory and Lewin’s Theory of Change were used to guide the design and
implementation of the intervention. These models may be applied by clinical practice providers
to present the opportunity of behavior change related to the screening and identification of
metabolic syndrome, thereby improving patient health outcomes (Bickman, 1987; Issel, 2014;
Lewin 1947; Rossi, Freeman, & Lipsey, 2004; Potvin, Gendron, Bilodeau, & Chabot, 2005).
The Program Theory (2005) details how a health program will affect participants, provide
guidance, and build a foundation for communication and action. Program Theory emphasizes the
importance of involving team members and key stakeholders in the project to make the
interventions more sustainable. For example, team members and key stakeholders signed
contracts to signify their commitment to the project. Furthermore, the theory also takes into
consideration health disparities and culturally bound health behaviors, which is important when
addressing metabolic syndrome (Healthy People, 2010). Determination of need and preferences
occurred through a needs assessment. Assessment took place at the population level with
collecting and reviewing data. Educating and monitoring took place at the direct service level.
Monitoring, the documentation of program performance to assess function, occurred at
reassessment and follow-up. Education was performed throughout the intervention (Potvin et al.,
2005; Rossi, Lipsey, & Freeman (2004)).
Lewin’s Theory of Change is a rational-linear change management model to guide
changes. The three stages of Lewin’s Change Theory include unfreezing, transition, and
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refreezing. Unfreezing is when a process, thought, behavior, mindset or knowledge is
interrupted. The transition stage is when there is a change in the interrupted process, thought,
behavior, mindset or knowledge. Refreezing is when the change becomes the new habit and
therefore the norm. If refreezing does not occur, it is easy to fall back into previous habits and
behaviors. Lewin’s Change Theory was used to identify barriers and facilitators to change, while
providing a framework. The theory was selected based on its strengths including versatility,
practicality, and simplicity. The transition phases included the opportunity to make adjustments
to this organizational service utilization plan as the project progressed during the transition
phase. Lewin’s Theory of Change helped to navigate short-term and long-term effects (Issel,
2014; Lewin, 1947; Manchester et al., 2014; Shirley, 2013).
In this project, the unfreezing was the identification of the gap in practice that patients are
rarely diagnosed with metabolic syndrome. Unfreezing was identified during the pursuit of a
different DNP project that would refer patients with metabolic syndrome to cardiopulmonary
exercise testing to guide tailored activity/exercise plans. The moving and freezing stage was the
presentation and delivery of the toolkit. This stage involved finding a way to seamlessly blend
screening for metabolic syndrome into a provider’s routine. In the last stage, the refreezing
occurs over time as providers adopt the new behavior. Based on provider feedback that will be
discussed later, the intervention made an impression on the provider’s perception and validity of
metabolic syndrome but did not change practice regarding use of ICD coding when metabolic
syndrome was screened and identified. Refreezing may require repeated reinforcement and
policy or procedural changes (Kritsonis, 2005; Sutherland, 2013).
The Program Theory (Potvin et al., 2005) and Lewin’s Change Theory (Lewin, 1947;
Shirley, 2013) complemented each other during this presentation and toolkit. For example,
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Program Theory was beneficial during the transition stage of Change Theory in determining if
improvements or changes in the delivery of the presentation and toolkit were needed.
Toolkit
Toolkit Objectives
This DNP project was a presentation of a toolkit to address the lack of screening,
identification, and coding of metabolic syndrome in primary care to an internal medicine clinic
group in Massachusetts (Site A). Upon invitation, this presentation was repeated at a family
medicine clinic in Montana (Site B).
The overarching goal of the presentation and toolkit was to increase provider awareness
and knowledge of metabolic syndrome, including the most current and widely accepted
definition, ICD coding and potential impact of using this diagnostic category for the practice.
Providers and staff were provided with a practical and easy-to-apply toolkit for the primary care
setting, including the presentation PowerPoint slides, Metabolic Syndrome Time Tool, ATP III
checklist of inclusion criteria to meet the definition of metabolic syndrome, ACPM clinical
reasoning of metabolic syndrome in the primary care setting, and ACPM patient education guide
(see Appendix B).
The DNP Student also wanted to gain an understanding of provider perception of
metabolic syndrome because, despite the evidence available, there are not significant changes
being made in primary care to include this ICD code and unrealized positive impacts on patient’s
health are being missed.
Target Population
Overall, the population of interest was primary care providers caring for adult patients,
eighteen years or older meeting the definition of metabolic syndrome or at risk of developing
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metabolic syndrome. The setting in which the Site A intervention was implemented and
evaluated was a large, for-profit internal medicine primary care clinic in Western Massachusetts.
There are seven providers at the clinic, four physicians, two nurse practitioners, and one
physician assistant. At the time of data analysis, 8,665 patients received care at the clinic and 23
patients were coded with metabolic syndrome. Site B is a small, rural, non-profit family
medicine clinic in Montana. There are two physicians and one physician assistant providing care
to an estimated 2,000 patients. At the time of data analysis, no patients at Site B were coded with
metabolic syndrome.
The presentation and toolkit was offered to the entire staff at Sites A and B, but the focus
was on primary care providers. The majority of providers reported familiarity with metabolic
syndrome but not regular use in practice. Site A was selected for the presentation and toolkit
delivery because the expected rates of metabolic syndrome were based on national and global
estimates of the prevalence of metabolic syndrome and the limited availability of individual
metabolic syndrome characteristics for the states of Massachusetts and Montana. It was assumed
by the DNP Student that both sites should have approximately one-third of their adult population
coded with metabolic syndrome.
Presentation of Toolkit
The PowerPoint and verbal presentation were provided on-site to healthcare staff,
including providers (Nurse Practitioner [NP], Physician Assistant [PA], Doctor of Medicine
[MD] and nurses [Registered Nurse and Licensed Practical Nurse]). The presentation was based
on the above review of literature and the 2009 Metabolic Syndrome Time Tool from the ACPM.
The intervention also included a toolkit based on the Time Tool and emphasized the inclusion of
metabolic syndrome in patient care, assessment, treatment planning, and follow-up. Key
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elements also included definition, impact, risk, and diagnosis. The use of metabolic syndrome in
prevention was accentuated. Critical elements included the definition of metabolic syndrome and
urgency and impact of lifestyle changes.
This project was not a research study and did not include practice patients or individual
patient data. Adherence to site policy and procedures were followed. Patient records were
HIPAA protected and office personnel retrieved needed health related information for the DNP
Student. Provider survey responses were kept anonymous. Risks identified for human subjects
from this intervention were minimal. Per DNP Project Committee, IRB approval was not needed
(U.S. Department of Health and Human Services [USDHHS], 2009).
Site A presentation and administration of the toolkit occurred in January 2016 with
follow-up in February 2016. The Site B presentation and toolkit delivery occurred in February
2016 with follow-up in March 2016. Regular e-mail communication occurred with the Site A
mentor leading up to the intervention and through follow-up. The Site B mentor was established
at the time of the intervention and assisted with data gathering and follow-up. Site A providers
were notified of the presentation and timeline of communication one month prior to the
presentation. Only one provider corresponded prior to the presentation via e-mail, expressing
skepticism over the validity of metabolic syndrome. Prior to the presentation, a pre-presentation
questionnaire was submitted to the providers. At site B, the DNP student was invited to present,
and the providers were notified by e-mail three days in advance. Clinic nurses were provided
with a short four-question survey assessing their readiness to participate in screening for
metabolic syndrome. A follow-up e-mail was sent to providers at Week 2. Content included
metabolic syndrome facts and information about the number of patients seen at Site A between
the ages of 45 and 65 who had diagnoses such as hypertension, type II diabetes, obesity, and high
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cholesterol. At Site A and Site B, the DNP student mentors generously retrieved needed
information for the DNP Student. The mentors gathered data for pre-intervention and follow-up
metabolic syndrome population data.
In order to achieve success of the DNP project, key stakeholders were engaged (see
signed Stakeholder Agreements in Appendix A). Stakeholders included the four physician
owners of Site A, the clinic manager, and DNP Student Mentor. Stakeholders did not sign
agreements at Site B due to the process of inviting the DNP Student to present. The DNP at the
internal medicine clinic (Site A) was the primary contact, mentor, and facilitator through the
project. This individual worked closely with the DNP student throughout the duration of the
project. Stakeholders also included the RN who assisted in gathering clinic data and all providers
who participated. Site B included two mentors, a physician and RN who assisted in data
collection and follow-up.
Outcomes
The outcomes from the presentation and toolkit were numerous. The presentation and
toolkit were well attended and well received. Additional information was obtained in surveys
prior to the presentation and after the presentation. At Site A and B, providers were surveyed
through pre-presentation, post-presentation, and follow-up surveys. Nurses were given a nurse
readiness survey. All survey responses are available in Appendix C. At Site A, six out of seven
providers (NP, PA, MD) completed the pre-presentation survey. At Site B, two out of three
providers (PA, MD) completed the pre-presentation survey.
The follow-up was a two-part process. The providers from each site were sent an online
survey through SurveyMonkey to assess the changes in their knowledge, perception, and
application of metabolic syndrome. At Site A, six out of seven providers completed the pre-
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presentation survey, five out of seven the post-presentation survey, and five out of seven the
follow-up survey. Three out of three nurses completed the nurse readiness survey. At Site B, two
out of three providers completed the pre-presentation survey, one out of three the postpresentation survey, and two out of three the follow-up survey. Three out of three nurses
completed the nurse readiness survey. Those who did not complete any survey leading up to
and/or the final follow-up survey are considered lost to follow-up at this time, but any partial
completion of the surveys still provided valuable information.
More specific feedback was collected from Site A. There was also a higher response rate
at Site A, as five out of seven or 71% of providers from Site A completed the follow-up survey
compared to two out of three or 66% of providers from Site B who completed the follow-up
survey.
Prior to the presentation, 23/8665 patients at Site A were coded with metabolic
syndrome. After the presentation and distribution of the toolkit, 25/8665 patients were coded
with metabolic syndrome. At Site B, no patients were coded with metabolic syndrome before or
after the DNP Project. At Site A, efforts were made by the clinic to look into insurance
reimbursement as well as electronic medical record (EMR) alerts. At the time of write-up, no
changes regarding insurance reimbursement and EMR alerts had been made. However, the DNP
student was reassured that these kinds of changes happen slowly.
The DNP student also investigated insurance reimbursement and discovered that
reimbursement information is quite limited. Requests were made repeatedly to three insurance
companies, but no responses were provided. Based on this experience, it is difficult to access any
information from insurers. An office NP or MD who is credentialed by the insurers would best
accomplish this investigation. Further lobbying efforts should be made with insurance companies
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to properly reimburse for these preventative visits, whether addressing primary, secondary, or
tertiary care.
Feedback from the survey included not only information on patient care but also
anecdotal feedback regarding personal changes of the providers and staff who attended the
conference. While the numbers of patients diagnosed with metabolic syndrome did not
significantly change, the common response implied that the impact of lifestyle choices and
changes along with prevention were valuable tools in considering patient counseling and
treatment plans.
There were many positive results from the collection of surveys. Provider answers spoke
to the efficacy of the intervention, benefits to patient care, value of metabolic syndrome, and
future patient care changes. Nurses overwhelmingly responded positively in willingness to
participate in patient care. Of note, providers responded that identification and treatment of
metabolic syndrome is useful in preventing atherosclerosis. Providers reported that the
presentation and toolkit helped them realize that discussing metabolic syndrome with patients
may help motivate them to be successful in lifestyle changes, and realize that lifestyle changes
are important. Providers also suggested they will engage in future patient education and
motivation to achieve patient lifestyle changes and prevention of metabolic syndrome.
All of the providers at Site A responded that the presentation and toolkit affected their
approach to metabolic syndrome. The intervention made them aware of the importance of
lifestyle changes and impact that patient education may have. Three Site A providers reported a
change in their practice regarding metabolic syndrome, specifying that they tried to recognize the
multiple symptoms of metabolic syndrome and to help at risk patients. Four Site A providers
reported counseling more patients on metabolic syndrome. Four providers also reported they felt
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that changing their practice was beneficial. Site B providers did not indicate a change in practice.
They did show a perceived value in the identification and treatment of metabolic syndrome in
atherosclerosis prevention. They also reported the definition of metabolic syndrome was well
defined.
Analysis of the nurse readiness survey shows that 100% of the nurses reported they
would be willing to assist in screening patients. Additionally, 100% of nurses identified that a
checklist and space for documentation would support them in screening patients. The criteria
table from the AHA/NHLBI found in Appendix B Toolkit Contents could be used for nurse
screening. Documentation would likely need to be individualized on a site-by-site basis,
dependent on the use of electronic health record.
Based on informal expressions such as e-mail and questions and statements prior to and
after the presentation, the DNP student had the impression that the providers overreported their
use of metabolic syndrome. This was also supported in survey responses. For example, there was
a noted discrepancy between the number of providers that reported using metabolic syndrome
codes and what was found on the pre-intervention assessment of charts. Based on provider
answers, there has been some self-reporting bias, particularly “often” or “frequently” as the EMR
statistics do not support this. Also, no provider definitions of metabolic syndrome specified
inclusion criteria, and the preferred guideline was not identified.
Self-reporting bias was noted when providers were asked if they currently use ICD-10
coding for patients diagnosed with metabolic syndrome. Three providers reported coding habits
ranging from rarely to frequently. This shows self-reporting bias because if rare, often, or
frequent ICD 10 coding of metabolic syndrome was used, the number of patients coded with
metabolic syndrome would be greater than 23 out of 8,665.
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Additional self-reporting bias was noted because providers answered questions based on
previous questions that were dependent on yes or no questions. Only three providers should
have responded questions 2, 3, &4 in this survey. This observation is also relevant to question 3
and question 4. This also reflects self-reporting bias because there was little change to the
number of patients diagnosed with metabolic syndrome, as seen below. However, it is noted that
the question style may have been confusing to the two providers who answered the irrelevant
questions.
When asked if the providers screen for metabolic syndrome, one provider reported rare
screening and the other reported often screening. This shows self-reporting bias because no
patients were coded with metabolic syndrome, therefore never screening would have been a
better response.
To further support suspected over-reporting of documentation, in April 2015, data was
collected on some of the characteristics of metabolic syndrome. The codes listed are ICD-9
because ICD-9 was in use at the clinic in April 2015. This is just a snapshot for a limited adult
population. There were 1,395 patients age 45–65 with 401 (hypertension). There were 1,271
patients age 45–65 with 278 (obesity). There were 341 patients age 45–65 with 250.0 (diabetes
without complications). Imagine the number of patients who also have low HDL, high LDL,
prehypertension, elevated fasting plasma glucose, and abdominal obesity or are maybe just
overweight. The numbers are staggering.
In summary, key results of the project included the following:
1. An educational intervention PowerPoint, verbal presentation, and metabolic
syndrome tool kit were presented to two clinical sites in January and February 2016.
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2. After the metabolic syndrome educational intervention, participants reported
increased knowledge of metabolic syndrome.
3. After 1 month, participants reported a change in their clinical approach to patients
with metabolic syndrome and a shift in their focus to prevention and lifestyle.
4. Yet, after 1 month, the number of patients coded with metabolic syndrome did not
increase.
5. Self-reporting bias was noted in provider survey responses.
6. In light of #4 and #5 above, regarding the persistent clinical inertia of providers and
self-reporting bias, further investigation is needed.
Discussion
Benefits of Toolkit
Benefits of the toolkit are numerous. For example, even though the guidelines and the
Time Tool are a few years old, they are still the most evidence-based information available. The
organization of the Time Tool is clear and easy to understand, as is the toolkit. The PowerPoint
succinctly communicates important information, the Time Tool provides relevant practice
knowledge, the clinical reference provides in-depth information, the patient guide is appropriate
for adults with metabolic syndrome, and the checklist is straightforward. Practical rationales are
also present throughout, to help providers see the value of these interventions despite the
additional time and resources needed.
The Toolkit also emphasizes the benefits of prevention and patient education. This is
valuable because the lifestyle changes are first-line interventions, due to safety and efficacy.
Finally, the toolkit communicates that using metabolic syndrome coding would be more effective
office visits, more comprehensive follow-up visits, more time to spend on counseling.
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Limitations
In the survey, providers reported limitations related to time for patient visits and
resources to support patients, as well as financial reimbursement. Some providers demonstrated
skepticism by questioning if the treatment for metabolic syndrome was really that different from
each individual component. There was also the appearance of self-reporting bias. Providers
commented on time constraints being major barriers for addressing metabolic syndrome as well
as screening and coding. One provider at Site B stated that they did not think the diagnosis of
metabolic syndrome would change treatment in the post-presentation survey.
Self-reporting bias was mostly speculated on questions regarding the use of metabolic
syndrome coding in patient care. For example, three Site A providers reported Rarely, Often, or
Frequent coding of patients diagnosed with metabolic syndrome even though the number of
patients coded with metabolic syndrome was very low. Another example is in the Site B followup survey. Providers there also reported, post-presentation, that they Sometimes code patients
with metabolic syndrome, but in the pre-presentation survey, they reported Rarely. However,
there was no change in coding of patients with metabolic syndrome on follow-up
communications with sites for population analysis. At Site A and B, some providers answered
questions on the follow-up survey that were not applicable based on the question and some of
these follow-up answers were contradictory. For example, in the follow-up survey providers
were instructed to answer questions two through question four only if they answered yes to
question on. Based on this, future consideration will be given to instruction wording, as this may
have been confusing to providers.
The higher response rate at Site A is of interest to the DNP Student because Site A was
identified by the DNP Student as having a gap in practice and the DNP Student then obtained
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permission to administer the presentation and toolkit. At Site B, the DNP Student was
completing clinical work for a different course. The DNP student advisor and mentor voluntarily
invited the DNP Student to present the project.
These surveys focused on qualitative data, which can be challenging to validate.
However, these are the data that are needed. Evidence and statistics are already present to show
the prevalence and impact of metabolic syndrome and benefits for positive patient outcomes if
recognized early and treated. Yet, even with clear percentages and statistics, metabolic syndrome
is not being used as it should be as diagnostic code in primary care.
Future Recommendations
Many researchers are focusing on all of the impacts of metabolic syndrome. It is well
known that the impact is far beyond just the current five characteristics used to diagnose and
identify metabolic syndrome. Other impacts include carbohydrate intolerance, endothelial
dysfunction, increased coagulation, decreased fibrinolysis, microalbuminuria, lipid disturbances,
pro-thrombic factors, and pro-inflammatory factors. More investigation is needed to address the
identification and coding of metabolic syndrome in primary care.
The CardioMetabolic Health Alliance Think Tank
(https://www.cardiometabolichealth.org/cardiometabolic-think-tank-releases-new-patient-caremodel-for-metabolic-syndrome.html) and others are working to create a new patient diagnosis
and care model. This is valuable for future improvements toward better screening, identification,
diagnosis and management of patients with metabolic syndrome and to address barriers providers
face in implementing the evidence-based practice. The DNP student agrees with the Think Tank
report in that diagnosis and team-based care coordination, use of social media, and
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considerations for reimbursement of ICD 10 coding for metabolic syndrome, in particular,
should be considered.
It is the DNP Student’s opinion that screening, identification, and treatment of metabolic
syndrome will not be commonplace until there is published common patient visit, monitoring,
and documentation standards specifically for metabolic syndrome, as well as insurance
reimbursement similar to diabetes. For example, diabetes patient care (ADA, 2014) includes a
history and physical performed two or three times a year, an annual foot exam, and laboratory
A1c testing every three or six months. There is also annual laboratory testing of a fasting lipid
profile, liver function tests, urine albumin secretion, and serum creatinine.
Conclusion
The five characteristics of metabolic syndrome are recognized by many healthcare
organizations such as ATP III, AHA, NHLBI, IDF, Endocrine Society, and many others. Use of
the ICD 10 code for metabolic syndrome can identify patients who are not being treated
aggressively enough and allow for preventive healthcare to slow or stop worsening health.
The purpose of this DNP project was to deliver a verbal presentation and PowerPoint, as
well as a toolkit for practice, with the intent of increasing providers’ knowledge and
identification of adult patients with metabolic syndrome in the primary care setting. The
presentation and toolkit was developed with Program Theory and Lewin’s Theory of Change,
ACPM Time Tool, and review of literature. Based on intervention pre-, post-, and follow-up
surveys, providers do feel that metabolic syndrome has value, which is supported by evidencebased guidelines and research. The majority of providers found that a toolkit addressing
metabolic syndrome in primary care affected their approach to metabolic syndrome. Metabolic
syndrome education can change the way providers discuss lifestyle changes and need for
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prevention with patients. Additionally, nurses are also willing to participate in patient metabolic
screening.
Information collected in these surveys does echo available data. Metabolic syndrome is
prevalent, but few providers identify or address the constellation of problems, preferring to
address each component individually. However, the providers also recognize the benefits of
using metabolic syndrome to emphasize prevention and lifestyle changes. It is the opinion of the
DNP student and others that metabolic syndrome does not fit easily into the current routine and
expectations of patient care that are dictated by the status quo and requirements from
organizations such as insurance companies, Medicare, and Medicaid. The responses from
providers begin to paint a clearer picture of what is needed to support the use of metabolic
syndrome as a diagnostic category.
The Metabolic Syndrome Time Tool from the American College of Preventive Medicine
is evidence-based, and its content and information are valuable for all providers until newer
guidelines and information become available. Addressing metabolic syndrome as an aggregate or
constellation versus individual problems promotes more effective and efficient identification,
diagnosis and care as well as a clearer emphasis on the need for lifestyle changes. In today’s
healthcare system, value is increasingly placed on prevention, as evidence is available on health
outcomes and political systems, such as the Affordable Care Act and Healthy People 2020. Yet,
if identification and diagnosis is not made first, prevention efforts are under realized and
incomplete.
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Sadie Russell Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q8 What is first line treatment of metabolic
syndrome?
Answered: 6

Skipped: 0

#

Responses

Date

1

weight loss

1/18/2016 9:31 AM

2

lifestyle choieces

1/18/2016 8:48 AM

3

Diet

1/18/2016 8:35 AM

4

Lifestyle modifications

1/18/2016 8:25 AM

5

weight loss

1/18/2016 7:09 AM

6

Lifestyle change diet exercise

1/13/2016 5:08 AM

8 / 10
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Sadie Russell Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q9 What is the goal of treating metabolic
syndrome?
Answered: 6

Skipped: 0

#

Responses

Date

1

decrease bmi

1/18/2016 9:31 AM

2

decreased weight, stable glucose, htn controlled

1/18/2016 8:49 AM

3

Control at, bp, glucose, lipids

1/18/2016 8:36 AM

4

to control the multiple factors that go into increasing risk for cardiac issues and preventing stroke such as controlling

1/18/2016 8:26 AM

DM, HTN, Hyperlipidemia, etc.
5

improve all parameters

1/18/2016 7:10 AM

6

Reduce the progression of sx

1/13/2016 5:09 AM

9 / 10
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Sadie Russell Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q10 What is your professional role?
Answered: 6

Skipped: 0

MD

DO

NP

PA

RN

LPN

CNA
Other (please
specify)
0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

MD

50.00%

3

DO

0.00%

0

NP

33.33%

2

PA

16.67%

1

RN

0.00%

0

LPN

0.00%

0

CNA

0.00%

0

Other (please specify)

0.00%

0

Total

#

6

Other (please specify)

Date

There are no responses.

10 / 10
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Post-presentation Survey

SurveyMonkey

Q2 Do you feel that identification and
treatment of metabolic syndrome is useful
in preventing atherosclerosis?
Answered: 5

Skipped: 0

#

Responses

Date

1

Yes

1/18/2016 5:20 PM

2

possibly

1/18/2016 4:08 PM

3

yes

1/18/2016 2:57 PM

4

Yes, I discuss lifestyle modifications with the majority of my patients and in the future I hope to have a discussion with

1/18/2016 2:15 PM

patients about the specifics of metabolic syndrome.
5

Yes

1/18/2016 2:08 PM
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q1 Have you changed your practice over
the past month regarding metabolic
syndrome?
Answered: 5

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

60.00%

3

No

40.00%

2

Total

5

#

If yes, why? If no, why?

Date

1

to help recognize at risk patients

3/23/2016 12:20 PM

2

Tried to recognize the multiple sx that make metabolic syndro

2/19/2016 2:33 AM

1 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q2 If yes to question 1, have you
coded more patients with metabolic
syndrome?
Answered: 5

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

80.00%

4

No

20.00%

1

Total

5

2 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q3 If yes to question 1, have you counseled
more patients on metabolic syndrome?
Answered: 5

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

80.00%

4

No

20.00%

1

Total

5

3 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q4 If yes to question 1, do you feel
changing your practice has been
beneficial?
Answered: 4

Skipped: 1

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

100.00%

4

No

0.00%

0

Total

4

4 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q5 Out of all your patients that you estimate
have metabolic syndrome, what percentage
of patients do you address metabolic
syndrome with during the patient visit?
Answered: 5

Skipped: 0

#

Responses

Date

1

I have always addressed these issues but have never coded for it so although I have coded for metabolic syndrome a

3/23/2016 12:22 PM

few more times in the past month I have not changed how many patients I speak to about it because I have always
had these discussions with my patients.
2

?

3/23/2016 10:19 AM

3

all of them

2/20/2016 6:15 AM

4

The problem here is that we only have time to address it during a physical exam. I only have up to four physical exams

2/19/2016 2:34 AM

scheduled in a visit and of those the percentage that may qualify for met metabolic syndrome
5

50

2/18/2016 7:04 PM

5 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q6 Do you screen patients for metabolic
syndrome?
Answered: 5

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patient population)

0.00%

0

2 = Sometimes (25 - 50% of my patient population)

20.00%

1

3 = Often (50 - 75% of my patient population)

60.00%

3

4 = Frequently (100% of my patient population)

20.00%

1

Total

5

#

Comment? Please share!

Date

1

Time constraints are always an issue

2/19/2016 2:35 AM

6 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q7 Do you use the ICD 10 (or 9) code for
patients diagnosed with metabolic
syndrome?
Answered: 5

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

40.00%

2

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

0.00%

0

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

60.00%

3

4 = Frequently (100% of my patient population)

0.00%

0

Total

5

#

Comment? Please share!

Date

1

Time constraints are an issue need red flags to Q me to diagnose

2/19/2016 2:36 AM
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q8 Do you counsel patients on metabolic
syndrome?
Answered: 5

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

0.00%

0

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

20.00%

1

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

60.00%

3

4 = Frequently (100% of my patient population)

20.00%

1

Total

5

#

Comment? Please share!

Date

1

Same comments as before

2/19/2016 2:36 AM

8 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q9 Does metabolic syndrome affect your
treatment plan for individual patients?
Answered: 5

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

20.00%

1

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

20.00%

1

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

60.00%

3

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

5

Comment? Please share!

Date

There are no responses.

9 / 10
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Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q10 What is your professional role?
Answered: 5

Skipped: 0

MD

DO

NP

PA

RN

LPN

CNA
Other (please
specify)
0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

MD

20.00%

1

DO

0.00%

0

NP

40.00%

2

PA

40.00%

2

RN

0.00%

0

LPN

0.00%

0

CNA

0.00%

0

Other (please specify)

0.00%

0

Total

#

5

Other (please specify)

Date

There are no responses.

10 / 10
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Appendix D
Site B SurveyMonkey Surveys and Results

Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q1 Do you screen patients for metabolic
syndrome?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patient population)

50.00%

1

2 = Sometimes (25 - 50% of my patient population)

0.00%

0

3 = Often (50 - 75% of my patient population)

50.00%

1

4 = Frequently (100% of my patient population)

0.00%

0

Total

2

#

Comment? Please share!

Date

1

not specific screen in in general screening tests

2/22/2016 12:43 PM

1 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q2 Do you use the ICD 10 (or 9) code for
patients diagnosed with metabolic
syndrome?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

100.00%

2

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

0.00%

0

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

0.00%

0

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

2 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q3 Do you counsel patients on metabolic
syndrome?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

50.00%

1

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

50.00%

1

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

0.00%

0

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

3 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q4 Does metabolic syndrome affect your
treatment plan for individual patients?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

0.00%

0

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

50.00%

1

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

50.00%

1

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

4 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q5 Describe or define metabolic syndrome.
Answered: 2

Skipped: 0

#

Responses

Date

1

specific criteria elevated triglycerides, qwaist size increased, fasting glucose elevated, bp elevated. cholestero;l

2/22/2016 12:46 PM

elevated and low hdl
2

3 of 5 criteria

2/22/2016 12:37 PM

5 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q6 What is the preferred guideline to follow
for metabolic syndrome?
Answered: 2

Skipped: 0

#

Responses

Date

1

follow labs and recheck 6 months

2/22/2016 12:46 PM

2

lidestyle changes and drugs

2/22/2016 12:37 PM

6 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q7 What are the five characteristics of
metabolic syndrome?
Answered: 2

Skipped: 0

#

Responses

Date

1

see previous answer

2/22/2016 12:46 PM

2

hypertension, elevated glucose, hypertriglyceridemia, abd obesity

2/22/2016 12:37 PM

7 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q8 What is first line treatment of metabolic
syndrome?
Answered: 2

Skipped: 0

#

Responses

Date

1

diet exercise wt loss

2/22/2016 12:46 PM

2

lifestyle modification

2/22/2016 12:38 PM

8 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q9 What is the goal of treating metabolic
syndrome?
Answered: 2

Skipped: 0

#

Responses

Date

1

wt loss and reduction of risk factors

2/22/2016 12:47 PM

2

reduce risk of morbidity

2/22/2016 12:38 PM

9 / 10
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Site B Pre-Presentation Questionnaire (Metabolic Syndrome)

SurveyMonkey

Q10 What is your professional role?
Answered: 2

Skipped: 0

MD

DO

NP

PA

RN

LPN

CNA
Other (please
specify)
0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

MD

100.00%

2

DO

0.00%

0

NP

0.00%

0

PA

0.00%

0

RN

0.00%

0

LPN

0.00%

0

CNA

0.00%

0

Other (please specify)

0.00%

0

Total

#

2

Other (please specify)

Date

There are no responses.

10 / 10
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Site B Clinic Post-presentation Survey

SurveyMonkey

Q1 Do you feel the definition of metabolic
syndrome is well defined?
Answered: 1

Skipped: 0

#

Responses

Date

1

yes

2/24/2016 7:03 AM

1/4
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Site B Clinic Post-presentation Survey

SurveyMonkey

Q2 Do you feel that identification and
treatment of metabolic syndrome is useful
in preventing atherosclerosis?
Answered: 1

Skipped: 0

#

Responses

Date

1

yes

2/24/2016 7:03 AM

2/4
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Site B Clinic Post-presentation Survey

SurveyMonkey

Q3 Do you feel that the diagnosis of
metabolic syndrome will change treatment
in individual patients?
Answered: 1

Skipped: 0

#

Responses

Date

1

no

2/24/2016 7:03 AM

3/4
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Site B Clinic Post-presentation Survey

SurveyMonkey

Q4 Does this educational intervention affect
your approach to metabolic syndrome?
Answered: 0

#

Skipped: 1

Responses

Date

There are no responses.

4/4
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q1 Have you changed your practice over
the past month regarding metabolic
syndrome?
Answered: 2

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

0.00%

0

No

100.00%

2

Total

#

2

If yes, why? If no, why?

Date

There are no responses.

1 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q2 If yes to question 1, have you
coded more patients with metabolic
syndrome?
Answered: 2

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

100.00%

2

No

0.00%

0

Total

2

2 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q3 If yes to question 1, have you counseled
more patients on metabolic syndrome?
Answered: 2

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

50.00%

1

No

50.00%

1

Total

2

3 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q4 If yes to question 1, do you feel
changing your practice has been
beneficial?
Answered: 2

Skipped: 0

Yes

No

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

Yes

100.00%

2

No

0.00%

0

Total

2

4 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q5 Out of all your patients that you estimate
have metabolic syndrome, what percentage
of patients do you address metabolic
syndrome with during the patient visit?
Answered: 2

Skipped: 0

#

Responses

Date

1

10

3/23/2016 3:52 PM

2

unknown

3/23/2016 10:41 AM

5 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q6 Do you screen patients for metabolic
syndrome?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patient population)

0.00%

0

2 = Sometimes (25 - 50% of my patient population)

50.00%

1

3 = Often (50 - 75% of my patient population)

50.00%

1

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

6 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q7 Do you use the ICD 10 (or 9) code for
patients diagnosed with metabolic
syndrome?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

0.00%

0

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

100.00%

2

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

0.00%

0

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

7 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q8 Do you counsel patients on metabolic
syndrome?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

0.00%

0

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

100.00%

2

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

0.00%

0

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

8 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q9 Does metabolic syndrome affect your
treatment plan for individual patients?
Answered: 2

Skipped: 0

0 = Never

1 = Rarely
(<25% of my...

2 = Sometimes
(25 - 50% of...

3 = Often (50
- 75% of my...

4 = Frequently
(100% of my...

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Answer Choices

Responses

0 = Never

0.00%

0

1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)

50.00%

1

2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)

0.00%

0

3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)

50.00%

1

4 = Frequently (100% of my patient population)

0.00%

0

Total

#

2

Comment? Please share!

Date

There are no responses.

9 / 10
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Site B Follow-up Survey (Metabolic Syndrome)

SurveyMonkey

Q10 What is your professional role?
Answered: 2

Skipped: 0

MD

DO

NP

PA

RN

LPN

CNA
Other (please
specify)
0%

10%

20%

30%

40%

Answer Choices

50%

60%

70%

80%

90%

100%

Responses

MD

100.00%

2

DO

0.00%

0

NP

0.00%

0

PA

0.00%

0

RN

0.00%

0

LPN

0.00%

0

CNA

0.00%

0

Other (please specify)

0.00%

0

Total

#

2

Other (please specify)

Date

There are no responses.

10 / 10
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Site B Clinic Nurse Survey

SurveyMonkey

Q1 Would you be willing to assist in
screening patients for metabolic syndrome
as you are rooming them?
Answered: 3

Skipped: 0

#

Responses

Date

1

yes

2/24/2016 8:45 AM

2

yes

2/23/2016 4:11 PM

3

yes

2/23/2016 12:55 PM
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Site B Clinic Nurse Survey

SurveyMonkey

Q2 If not, why?
Answered: 1

Skipped: 2

#

Responses

Date

1

na

2/23/2016 12:55 PM
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Site B Clinic Nurse Survey

SurveyMonkey

Q3 What would support you to complete
this additional patient screening?
Answered: 3

Skipped: 0

#

Responses

Date

1

would need appropriate place for screening and documentation in cerner

2/24/2016 8:46 AM

2

Screens on the Ehr for documenting the areas necessary to diagnose Metabolic syndrome. Triggers to do waist

2/23/2016 4:15 PM

measuremnts etc.
3

a short template of questions

2/23/2016 12:55 PM
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